1 week Ago By Defense World Staff
Arrowstreet Capital Limited Partnership bought a new stake in shares of Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH – Free Report ) (TSE:AUP) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,075,911 shares of the biotechnology company’s stock, valued at approximately $9,662,000.
Arrowstreet Capital Limited Partnership owned 0.75% of Aurinia Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Other hedge funds and other institutional investors also recently made changes to their positions in the company.
State Street Corp increased its position in Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after purchasing an additional 64,949 shares during the period.
Barclays PLC increased its position in shares of Aurinia Pharmaceuticals by 187.6% during the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after buying an additional 143,072 shares during the period.
Blue Trust Inc. raised its stake in Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter.
Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock worth $57,000 after buying an additional 6,174 shares in the last quarter. Charles Schwab Investment Management Inc.
boosted its position in Aurinia Pharmaceuticals by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc.
now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after acquiring an additional 89,940 shares in the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $135,000.
Institutional investors own 36.83% of the company’s stock. Insider Activity In other Aurinia Pharmaceuticals news, CFO Joseph M.
Miller sold 61,859 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $494,872.
00. Following the completion of the sale, the chief financial officer now directly owns 633,515 shares in the company, valued at approximately $5,068,120. This trade represents a 8.
90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, insider Greg Keenan sold 8,305 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, March 7th.
The stock was sold at an average price of $8.23, for a total transaction of $68,350.15.
Following the completion of the transaction, the insider now directly owns 153,484 shares of the company’s stock, valued at $1,263,173.32. This trade represents a 5.
13 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last ninety days, insiders sold 343,898 shares of company stock worth $2,753,094.
Insiders own 4.30% of the company’s stock. Wall Street Analysts Forecast Growth Get Our Latest Analysis on Aurinia Pharmaceuticals Aurinia Pharmaceuticals Trading Down 3.
0 % Shares of NASDAQ AUPH opened at $7.81 on Monday. The stock has a market cap of $1.
07 billion, a P/E ratio of -52.06 and a beta of 1.26.
The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.
11. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.
71 and a 1 year high of $10.67. The firm has a 50-day moving average of $8.
10 and a 200 day moving average of $8.09. Aurinia Pharmaceuticals Profile ( Free Report ) Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.
It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd. Read More Five stocks we like better than Aurinia Pharmaceuticals Consumer Staples Stocks, Explained Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential? What is Forex and How Does it Work? Disney 2025 Shareholders: Major Updates for Investors Industrial Products Stocks Investing Advance Auto Parts Stock: A Classic Rebound Play in the Making Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
